UNCY

Unicycive Therapeutics Inc. (UNCY) | Rumor.io

Unicycive Therapeutics

UNCY

Attention (50-day avg)0%

Attention rank (50-day avg)#2,219

Bullish sentiment (50-day avg)72%

Price to earnings ratio-2.78

Market capitalization127.1M

Earnings per share-1.75

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-26.6M

Social

What share of all stock conversation is about UNCY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Sep 29

Unicycive Therapeutics, Inc. has resubmitted its New Drug Application (NDA) for oxylanthanum carbonate, with a potential approval timeline of 6 months or less, depending on the inspection of the original vendor.
The company has added a second third-party manufacturing facility, which has already passed FDA inspections, to secure supply chain redundancy and potentially expedite approval.
The FDA has assigned an inspection for the original vendor, which could lead to a shorter approval timeline, and Unicycive plans to keep both vendors in place to maintain supply chain redundancy.

Generated by AI

Sentiment

Of the messages about UNCY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	95.65% +45.65	76.09% +8.52	79.12% +3.28
Bearish	0%	4.35% -45.65	23.91% -8.52	20.88% -3.28

Bullish· Jul 2

$UNCY is expected to rebound after a market overreaction to an FDA "rejection" letter, creating a potential opportunity for a strong run in the next 6 months.
The company's drug has shown no concerns about efficacy or safety, and approval seems imminent, which could lead to a significant price increase.
$UNCY is expected to reach $8-$10 by the end of the year, with some analysts predicting it could even surpass $10 by Thanksgiving, making it a potentially lucrative investment opportunity.

Bearish· Jul 1

The FDA's failure to inspect the manufacturing site within the required timeframe has led to a potential 5-12 month delay, resulting in a 40% drop in the stock price.
The company's management, led by Dr. Gupta, has been criticized for a major execution failure, with some investors questioning their competence and potentially even their honesty.
The stock's price drop to its 52-week low has led to excessive short selling, with some analysts predicting that the stock could drop to $3 if the company continues to tap the ATM and fails to address the manufacturing issues.

Generated by AI

Topics

Of the messages about UNCY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	89.47%	89.47%	93.75%	76.21%
Technical Analysis	0%	0%	0%	10.32%
Analysts	10.53%	10.53%	6.25%	10.65%
Controversies	0%	0%	0%	2.83%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Analysts· Mar 9

Maxim Group analyst Jason McCarthy maintains Unicycive Therapeutics with a Buy rating and raises the price target from $3 to $6.
HC Wainwright maintains a Buy rating for Unicycive Therapeutics with a price target of $8, representing a 315% upside.
EF Hutton initiates coverage on Unicycive Therapeutics with a Buy rating and a price target of $5, indicating a 159% upside.

Announcements· Jun 30

Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease.
The CRL was issued due to previously identified manufacturing deficiencies at a third-party facility, with the FDA not raising concerns related to clinical data or safety.
The company is optimistic about a quick resubmission after the FDA inspection, with CEO Shalabh Gupta stating that the third-party manufacturing facility can meet FDA standards to support an approval.

Technical Analysis· Mar 13

$UNCY has a price target of $5 from UF Hutton and $8 from HC Wainwright, with a current price above $3.
The stock is expected to continue its uptrend, with a potential target of $3.10 if it holds above $2.60.
The stock has a clear skies chart trend and has crossed over its VWAP, indicating a strong upward momentum.

Generated by AI

Community

Of the messages about UNCY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	75.93%	73.02%	76%	59.63%
Newcomers	24.07%	26.98%	24%	40.37%

Regulars· Sep 29

The company has resubmitted its New Drug Application for oxylanthanum carbonate, which includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor and 12 months of OLC drug product stability data.
The resubmission package is expected to be accepted by the FDA within 30 days, and the new assigned PDUFA date is expected to be in late March 2027.
The company plans to seek FDA alignment on a shorter approval timeline if the original third-party manufacturing vendor is inspected and deemed cGMP-compliant, and intends to keep both drug product vendors to maintain supply chain redundancy.

Newcomers· Jun 30

Many newcomers are shorting UNCY, citing the company's low probability of getting FDA approval for its oxylanthum carbonate drug.
Some newcomers are holding onto their UNCY shares, hoping for a recovery, while others are using the stock as a "bag holder" to ride out potential gains.
Newcomers are discussing the potential impact of UNCY's FDA Complete Response Letter, with some referencing the stock's price action, including its low price, heavy volume, and bearish technical indicators.

Generated by AI

News

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

1d agoYahoo Finance

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

1d agoMorningstar

Unicycive Therapeutics faces securities class action lawsuit over public statements

1d agoInvesting.com

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026

Detailed price information for Unicycive Therapeutics Inc (UNCY-Q) from The Globe and Mail including charting and trades.

5d agoThe Globe and Mail

Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

6d agoMorningstar

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026

NewMediaWire Press Release.

7d agoThe Globe and Mail

Also Discussed

Investors talking about UNCY also mention

#	Name	Attention
1	Cingulate Inc.CING	0%new
2	AMAM - Ambrx Biopharma Inc.	——
3	Cardio Diagnostics Holdings, Inc.CDIO	0%0
4	Nuvation Bio Inc.NUVB	0%0
5	Ardelyx IncARDX	0.01%+0.01
6	Grace Therapeutics, Inc.GRCE	0%new
7	Palvella Therapeutics, Inc.PVLA	0%new
8	BG Staffing IncBGSF	0%new
9	Fortress Biotech, Inc.FBIO	0%0
10	Mega Matrix Inc.MPU	0%0

Unicycive Therapeutics Inc.

Healthcare
Biotechnology

Unicycive Therapeutics Inc. is a biotechnology company primarily focused on the development and commercialization of therapies for patients with kidney disease. The company works extensively on creating novel and transformative treatments, addressing significant unmet medical needs in nephrology. One of its leading candidates targets hyperphosphatemia, a common complication in patients with chronic kidney disease. Unicycive Therapeutics employs innovative drug discovery techniques to advance its pipeline of clinical and preclinical programs, aiming to improve patient quality of life and healthcare outcomes. The company's role in the biotechnology sector is to drive advancements in kidney therapy solutions, contributing to medical research and offering potential breakthroughs in treatments for chronic conditions. Founded with a commitment to science-driven approaches, Unicycive Therapeutics operates within a competitive and rapidly evolving market, collaborating with industry and academic partners to accelerate the development of its therapeutic solutions.

Website

Location

1975 West El Camino Real

Mountain View, CA, 94040

United States

Social

What share of all stock conversation is about UNCY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Sep 29

Unicycive Therapeutics, Inc. has resubmitted its New Drug Application (NDA) for oxylanthanum carbonate, with a potential approval timeline of 6 months or less, depending on the inspection of the original vendor.
The company has added a second third-party manufacturing facility, which has already passed FDA inspections, to secure supply chain redundancy and potentially expedite approval.
The FDA has assigned an inspection for the original vendor, which could lead to a shorter approval timeline, and Unicycive plans to keep both vendors in place to maintain supply chain redundancy.

Generated by AI

Sentiment

Of the messages about UNCY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	95.65% +45.65	76.09% +8.52	79.12% +3.28
Bearish	0%	4.35% -45.65	23.91% -8.52	20.88% -3.28

Bullish· Jul 2

$UNCY is expected to rebound after a market overreaction to an FDA "rejection" letter, creating a potential opportunity for a strong run in the next 6 months.
The company's drug has shown no concerns about efficacy or safety, and approval seems imminent, which could lead to a significant price increase.
$UNCY is expected to reach $8-$10 by the end of the year, with some analysts predicting it could even surpass $10 by Thanksgiving, making it a potentially lucrative investment opportunity.

Bearish· Jul 1

The FDA's failure to inspect the manufacturing site within the required timeframe has led to a potential 5-12 month delay, resulting in a 40% drop in the stock price.
The company's management, led by Dr. Gupta, has been criticized for a major execution failure, with some investors questioning their competence and potentially even their honesty.
The stock's price drop to its 52-week low has led to excessive short selling, with some analysts predicting that the stock could drop to $3 if the company continues to tap the ATM and fails to address the manufacturing issues.

Generated by AI

Topics

Of the messages about UNCY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	89.47%	89.47%	93.75%	76.21%
Technical Analysis	0%	0%	0%	10.32%
Analysts	10.53%	10.53%	6.25%	10.65%
Controversies	0%	0%	0%	2.83%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Analysts· Mar 9

Maxim Group analyst Jason McCarthy maintains Unicycive Therapeutics with a Buy rating and raises the price target from $3 to $6.
HC Wainwright maintains a Buy rating for Unicycive Therapeutics with a price target of $8, representing a 315% upside.
EF Hutton initiates coverage on Unicycive Therapeutics with a Buy rating and a price target of $5, indicating a 159% upside.

Announcements· Jun 30

Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease.
The CRL was issued due to previously identified manufacturing deficiencies at a third-party facility, with the FDA not raising concerns related to clinical data or safety.
The company is optimistic about a quick resubmission after the FDA inspection, with CEO Shalabh Gupta stating that the third-party manufacturing facility can meet FDA standards to support an approval.

Technical Analysis· Mar 13

$UNCY has a price target of $5 from UF Hutton and $8 from HC Wainwright, with a current price above $3.
The stock is expected to continue its uptrend, with a potential target of $3.10 if it holds above $2.60.
The stock has a clear skies chart trend and has crossed over its VWAP, indicating a strong upward momentum.

Generated by AI

Community

Of the messages about UNCY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	75.93%	73.02%	76%	59.63%
Newcomers	24.07%	26.98%	24%	40.37%

Regulars· Sep 29

The company has resubmitted its New Drug Application for oxylanthanum carbonate, which includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor and 12 months of OLC drug product stability data.
The resubmission package is expected to be accepted by the FDA within 30 days, and the new assigned PDUFA date is expected to be in late March 2027.
The company plans to seek FDA alignment on a shorter approval timeline if the original third-party manufacturing vendor is inspected and deemed cGMP-compliant, and intends to keep both drug product vendors to maintain supply chain redundancy.

Newcomers· Jun 30

Many newcomers are shorting UNCY, citing the company's low probability of getting FDA approval for its oxylanthum carbonate drug.
Some newcomers are holding onto their UNCY shares, hoping for a recovery, while others are using the stock as a "bag holder" to ride out potential gains.
Newcomers are discussing the potential impact of UNCY's FDA Complete Response Letter, with some referencing the stock's price action, including its low price, heavy volume, and bearish technical indicators.

Generated by AI

Unicycive Therapeutics

Social

Sep 29

Bullish· Jul 2

Bearish· Jul 1

Analysts· Mar 9

Announcements· Jun 30

Technical Analysis· Mar 13

Regulars· Sep 29

Newcomers· Jun 30

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

Unicycive Therapeutics faces securities class action lawsuit over public statements

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026

Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026

Also Discussed

Unicycive Therapeutics Inc.

Company Information

Location

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

Unicycive Therapeutics faces securities class action lawsuit over public statements

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026

Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026

Also Discussed

Social

Sep 29

Bullish· Jul 2

Bearish· Jul 1

Analysts· Mar 9

Announcements· Jun 30

Technical Analysis· Mar 13

Regulars· Sep 29

Newcomers· Jun 30